As a result of reports by others of the properties of heterologous antilymphoid-tissue sera (ALS)1-7 and the results of our own experiences in the laboratory with the use of heterologous antithymus serum as an immunosuppressive agent,8,9 we have continued the trial of horse antihuman thymus serum (HAHTS) in clinical renal allografting. For reasons outlined previously, the serum has been given only as an adjuvant to azathioprine and prednisone, and this limited trial was constructed primarily to assess the problems of its administration. Our decision to use heterologous antithymus tissue serum rather than sera produced by the injection of other lymphoid tissues was also influenced by a report that antithymus sera may provide more effective immunosuppression than other varieties of ALS.10
This report reviews 36 consecutive renal transplant patients, treated with HAHTS, who have been studied for 6 to 18 months following transplantation. The early progress of some
Shorter RG, Hallenbeck GA, Anderson CF, Johnson WJ, DeWeerd JH, Danielson GK. Further Studies of Antilymphoid Sera in Clinical Renal Allotransplantation. Arch Surg. 1970;100(2):132–135. doi:10.1001/archsurg.1970.01340200020004
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: